- Previous Close
1,543.00 - Open
1,543.00 - Bid 1,547.00 x --
- Ask 1,548.00 x --
- Day's Range
1,470.00 - 1,536.00 - 52 Week Range
937.10 - 2,080.00 - Volume
34,741 - Avg. Volume
37,838 - Market Cap (intraday)
566.356M - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
45.24 - EPS (TTM)
0.33 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
www.brainsway.comRecent News: BWAY.TA
View MorePerformance Overview: BWAY.TA
Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BWAY.TA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BWAY.TA
View MoreValuation Measures
Market Cap
582.30M
Enterprise Value
414.45M
Trailing P/E
46.49
Forward P/E
36.36
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.31
Price/Book (mrq)
2.53
Enterprise Value/Revenue
2.74
Enterprise Value/EBITDA
16.84
Financial Highlights
Profitability and Income Statement
Profit Margin
7.12%
Return on Assets (ttm)
1.11%
Return on Equity (ttm)
5.62%
Revenue (ttm)
41.02M
Net Income Avi to Common (ttm)
2.92M
Diluted EPS (ttm)
0.33
Balance Sheet and Cash Flow
Total Cash (mrq)
69.34M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
4.06M